China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Non-Current Debt of $644390.0 for Q1 2026, up 569.4% year-over-year from $96264.0 in Q1 2025, and up 781.49% quarter-over-quarter from $73102.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Non-Current Debt history runs 8 years deep, the most recent figure standing at $644390.0 for Q1 2026.
- In Q1 2026, Non-Current Debt rose 569.4% year-over-year to $644390.0; the TTM figure through Mar 2026 stood at $644390.0 (up 569.4% YoY), while the FY2026 annual figure was $644390.0, up 569.4% from the prior year.
- Non-Current Debt for Q1 2026 stood at $644390.0, up from $73102.0 in the prior quarter.
- The five-year high for Non-Current Debt was $1.1 million in Q1 2022, with the low at $73102.0 in Q3 2025.
- The 5-year median for Non-Current Debt is $116236.5 (2024), against an average of $299140.5.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt plunged 90.76% in 2022, then soared 569.4% in 2026.
- China SXT Pharmaceuticals' Non-Current Debt stood at $1.1 million in 2022, then plunged by 90.51% to $106575.0 in 2023, then grew by 8.23% to $115344.0 in 2024, then tumbled by 36.62% to $73102.0 in 2025, then surged by 781.49% to $644390.0 in 2026.
- Business Quant data shows SXTC's Non-Current Debt at $644390.0 in Q1 2026, $73102.0 in Q3 2025, and $96264.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 130.00 Mn |
| 10 | China SXT Pharmaceuticals | 32,029.07 | -28.14 Mn | - | 644,390.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 644,390.00 |
| Sep 30, 2025 | 73,102.00 |
| Mar 31, 2025 | 96,264.00 |
| Sep 30, 2024 | 115,344.00 |
| Mar 31, 2024 | 117,129.00 |
| Sep 30, 2023 | 106,575.00 |
| Mar 31, 2023 | 117,862.00 |
| Mar 31, 2022 | 1.12 Mn |
| Mar 31, 2021 | 12.15 Mn |
| Sep 30, 2020 | 15,213.00 |
| Mar 31, 2020 | 36,511.00 |
| Sep 30, 2019 | 55,052.00 |
| Mar 31, 2019 | 41,706.00 |